Axel Bode

413 total citations
6 papers, 329 citations indexed

About

Axel Bode is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Cancer Research. According to data from OpenAlex, Axel Bode has authored 6 papers receiving a total of 329 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 6 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Cancer Research. Recurrent topics in Axel Bode's work include Radiopharmaceutical Chemistry and Applications (6 papers), Prostate Cancer Treatment and Research (6 papers) and Cancer, Lipids, and Metabolism (3 papers). Axel Bode is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (6 papers), Prostate Cancer Treatment and Research (6 papers) and Cancer, Lipids, and Metabolism (3 papers). Axel Bode collaborates with scholars based in Germany. Axel Bode's co-authors include Kambiz Rahbar, M. Claesener, Martin Bögemann, Matthias Weckesser, Anna Yordanova, Matthias Schmidt, Hojjat Ahmadzadehfar, Lars Stegger, Elisabeth Eppard and Alexander Heinzel and has published in prestigious journals such as Journal of Nuclear Medicine, Clinical Nuclear Medicine and Kölner Universitäts PublikationsServer (Universität zu Köln).

In The Last Decade

Axel Bode

6 papers receiving 328 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Axel Bode Germany	4	307	301	120	37	19	6	329
Stephan Neubauer Germany	3	320 1.0×	414 1.4×	80 0.7×	25 0.7×	7 0.4×	4	442
Carl Diedrich Schlenkhoff Germany	9	466 1.5×	454 1.5×	166 1.4×	39 1.1×	40 2.1×	12	523
Fabian Spohn Germany	4	267 0.9×	317 1.1×	74 0.6×	21 0.6×	9 0.5×	5	356
Ramin Alipour Australia	11	169 0.6×	169 0.6×	111 0.9×	20 0.5×	39 2.1×	26	270
Anne Thieme Germany	5	252 0.8×	193 0.6×	64 0.5×	32 0.9×	32 1.7×	6	286
Melanie Hohberg Germany	11	316 1.0×	289 1.0×	90 0.8×	36 1.0×	17 0.9×	23	379
Leon Will Germany	6	372 1.2×	463 1.5×	102 0.8×	26 0.7×	9 0.5×	8	524
Gesche Wieser Germany	7	239 0.8×	345 1.1×	101 0.8×	8 0.2×	41 2.2×	9	448
Sebastian Schmuck Germany	7	280 0.9×	330 1.1×	62 0.5×	10 0.3×	12 0.6×	12	383
Ross D. Merkin United States	7	173 0.6×	172 0.6×	119 1.0×	29 0.8×	12 0.6×	22	292

Countries citing papers authored by Axel Bode

Since Specialization

Citations

This map shows the geographic impact of Axel Bode's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Axel Bode with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Axel Bode more than expected).

Fields of papers citing papers by Axel Bode

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Axel Bode. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Axel Bode. The network helps show where Axel Bode may publish in the future.

Co-authorship network of co-authors of Axel Bode

This figure shows the co-authorship network connecting the top 25 collaborators of Axel Bode. A scholar is included among the top collaborators of Axel Bode based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Axel Bode. Axel Bode is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Rahbar, Kambiz, Matthias Schmidt, Alexander Heinzel, et al.. (2016). Response and tolerability after a single dose of Lu-177-PSMA-617 in patients with metastatic castration resistant prostate cancer: a multicenter Study. Kölner Universitäts PublikationsServer (Universität zu Köln). 1 indexed citations

2.

Bode, Axel, et al.. (2016). Benefit of 68Ga-PSMA-PET/CT in Patients Considered for 223Ra-Dichloride Therapy. Clinical Nuclear Medicine. 41(12). 951–952. 5 indexed citations

3.

Roll, Wolfgang, Axel Bode, Matthias Weckesser, Martin Bögemann, & Kambiz Rahbar. (2016). Excellent Response to 177Lu-PSMA-617 Radioligand Therapy in a Patient With Advanced Metastatic Castration Resistant Prostate Cancer Evaluated by 68Ga-PSMA PET/CT. Clinical Nuclear Medicine. 42(2). 152–153. 13 indexed citations

4.

Rahbar, Kambiz, Axel Bode, Matthias Weckesser, et al.. (2016). Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer. Clinical Nuclear Medicine. 41(7). 522–528. 141 indexed citations

5.

Rahbar, Kambiz, Matthias Schmidt, Alexander Heinzel, et al.. (2016). Response and Tolerability of a Single Dose of¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis. Journal of Nuclear Medicine. 57(9). 1334–1338. 168 indexed citations

6.

Rahbar, Kambiz, Axel Bode, Matthias Weckesser, et al.. (2016). Radioligand Therapy with Lu-177-PSMA-617 may improve survival in Patients with Metastatic Prostate Cancer. 57. 142–142. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact